Chemotherapy side effect predicting Oxford biotech secures CE marking
Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy.
New research supports the Oxford University Incubator startup’s challenge to Amazon Mechanical Turk’s dominance in sourcing participants for social science studies.
Following research showing Oxford University has produced more founders of billion-dollar startups than any other institution in Europe, Oxford University Innovation’s Gregg Bayes-Brown takes a closer look at the founders, their ties to Oxford, and the companies they’ve launched.
Oxford University Innovation’s management consultancy division to restructure as separate entity to scale up interactions and business on the world stage.
Oxford spinout Celleron Therapeutics raises funding from South Korean consortium of investors for small molecule treatments.
OxSonics, an Oxford University spinout established in 2013 to develop ultrasound therapeutics, has secured £9.4m in series B equity financing, bringing its total external fundraising to £14.2m.
Oxford University Innovation launches 24 companies in 2016 with a combined £52.6m in early stage funding, setting a new record in spinout generation for the UK and Europe.
HTC Vive and virtual reality distance learning platform Engage to showcase the LIFE project from the University of Oxford.
Oxford University spinout PrOXisense secures £330,000 in round led by Parkwalk Advisors for the development of sensors in extreme environments.
Circadian Therapeutics aims to develop therapeutics and diagnostics for modulation of the body's circadian rhythms.